Cell-based therapies for rheumatoid arthritis: opportunities and challenges

• Published in: Therapeutic advances in musculoskeletal disease Vol. 14; p. 1759720X221100294
• Main Authors: Li, Yu-Jing, Chen, Zhu
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 2022; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Musculoskeletal diseases; Nonsteroidal anti-inflammatory drugs; Review; Rheumatoid arthritis; regulatory T cells; chimeric antigen receptor T cell; rheumatoid arthritis; mesenchymal stem cells
• ISSN: 1759-720X; 1759-7218
• DOI: 10.1177/1759720X221100294

Rheumatoid arthritis (RA) is the most common immune-mediated inflammatory disease characterized by chronic synovitis that hardly resolves spontaneously. The current treatment of RA consists of nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, conventional disease-modifying antirheumatic drugs (cDMARDs), biologic and targeted synthetic DMARDs. Although the treat-to-target strategy has been intensively applied in the past decade, clinical unmet needs still exist since a substantial proportion of patients are refractory or even develop severe adverse effects to current therapies. In recent years, with the deeper understanding of immunopathogenesis of the disease, cell-based therapies have exhibited effective and promising interventions to RA. Several cell-based therapies, such as mesenchymal stem cells (MSC), adoptive transfer of regulatory T cells (Treg), and chimeric antigen receptor (CAR)-T cell therapy as well as their beneficial effects have been documented and verified so far. In this review, we summarize the current evidence and discuss the prospect as well as challenges for these three types of cellular therapies in RA.